Critical appraisal:Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al 2017 2
From Cancer Guidelines Wiki
Risk of bias assessment: randomised controlled trial
Was the trial double-blinded?
- Outcomes not blinded, substantial side-effects, or not reported.
Was the treatment allocation schedule concealed?
- No concealment or unclear (e.g. no approach described, open randomisation lists, person doing recruitment tossing a coin).
Were all randomised participants included in the analysis?
- Exclusions not likely to cause bias (>80% follow-up for all groups, <5% difference in follow-up between groups)
The field below is not considered when calculating the risk of bias rating
Overall risk of bias
|High risk of bias||Additional comments: Please replace this text and include any additional comments in regards to your risk of bias rating|
- Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 2017 Jun 8;376(23):2211-2222 Available from: http://www.ncbi.nlm.nih.gov/pubmed/28591523.
- Assigned to
- Topic area
- Clinical question
Section below only relevant for Cancer Council Project Officer